Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.

Xinwei HuaMario KratzRachel C MalenJames Y DaiSara LindströmYingye ZhengPolly A Newcomb

Published in: British journal of cancer (2021)

Our results support the role of chronic inflammation in CRC progression and suggested several post-treatment inflammatory biomarkers, particularly IL-6, are promising prognostic markers for stage II-III CRC patients.

Keyphrases

end stage renal disease
patient reported outcomes
combination therapy
replacement therapy